Farmanews.com

Notas de Prensa  

Actualidad. 11 de marzo de 2019
Under the terms of the collaboration, ark biosciences will utilize the marketing authorization holder (mah) scheme to accelerate drug development and wuxi sta will provide an integrated solution in process r&d and manufacturing.

WuXi STA and Ark Biosciences Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Ark Biosciences, a global biotech company focusing on innovative drug discovery and development, especially in the area of viral infection and respiratory disease, today announced a strategic partnership for CMC development and manufacturing.

 

 

Ark Biosciences’ pipeline includes active discovery programs of its own, those of its partners, as well as in-licensed drug assets for clinical development. Ark’s leading program, a novel respiratory syncytial virus (RSV) F-protein inhibitor Ziresovir (AK0529), has completed three phase I clinical trials and is currently in global multi-center phase II clinical trial. The company also entered into a license agreement with Roche in August 2018 for the global rights of a potential new standard-of-care treatment for idiopathic pulmonary fibrosis.

 

WuXi STA was selected as the strategic partner thanks to its industry leading “end-to-end” CMC platform for new drug development from preclinical to commercial – for both API and finished dosage forms – as well as its expertise and track record for meeting global quality standards. The company is at the forefront of implementing China’s MAH pilot program and is helping many domestic innovative drug development partners. By using WuXi STA, partners are able to optimize manufacturing processes, significantly reduce commercial production costs, mitigate business risk, and improve operational efficiency.

 

“We’re delighted to partner with such a well-respected, world-class CDMO such as WuXi STA,” said Dr. Jim Wu, CEO of Ark Biosciences. “WuXi STA’s enabling end-to-end CMC platform, scale, and innovation capabilities will help us to move our drug candidates from the clinical-stage to commercialization more efficiently.

 

Dr. Minzhang Chen, CEO of WuXi STA, commented: “Our mission is to empower and accelerate customers to develop innovative drugs from clinical to commercial – faster and more efficiently. We are delighted to become the strategic partner of Ark Biosciences and look forward to helping them advance their drug candidates towards the clinic, bringing innovative medicines for the benefit of patients around the world.”

 

 

About ARK BIOSCIENCES

ARK BIOSCIENCES is a global biotechnology company focusing on innovative drug discovery and development, especially in the fields of infection and respiratory disease, for world-wide markets. It has its corporate office in the Zhangjiang Hi-tech Park of Shanghai, and its R&D Center in Suzhou Biobay, the heart of pharmaceutical innovation in China. ARK BIOSCIENCES has its own active discovery programs, active development partnerships, and licensed drug assets under development. 

For more information, please visit:

www.arkbiosciences.com  

 

About WuXi STA

STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with operations in China and the United States. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for Active Pharmaceutical Ingredients (APIs) and finished dosage forms.

For more information, please visit: http://www.STApharma.com

Subir  

Subir notas de prensa y convocatorias

Próximas convocatorias   

No hay próximas convocatorias
Ver todas

Especialidades  

Busca notas de prensa por especialidad médica o enfermedad.



Ver todas

Archivo  

Busca notas de prensa por su fecha de edición.

  Selecciona el año


Copyright © 2019, Farmavet, S.L. Todos los derechos reservados.